{
    "nct_id": "NCT06760819",
    "official_title": "A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations",
    "inclusion_criteria": "* Documented histologically or cytologically confirmed locally advanced, unresectable or metastatic solid tumor cancer (colorectal carcinoma; biliary tract cancer; bladder and urothelial tract cancer; cervical cancer; endometrial cancer; other solid tumor cancer, excluding NSCLC)\n* Participant must be â‰¥18 years of age or over the legal age of consent\n* Patients who have received prior standard therapy appropriate for their tumor type and stage of disease, or who have no satisfactory alternative treatments\n* Documented activating HER2 mutation\n* At least one measurable lesion that would qualify as a target lesion by RECIST 1.1 criteria\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Primary diagnosis of non-small cell lung cancer (NSCLC)\n* Prior treatment with a HER2 tyrosine kinase inhibitor (TKI)\n* Active brain metastases\n* Uncontrolled, severe, intercurrent illness",
    "miscellaneous_criteria": ""
}